| Título: | Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma |
| Autores: |
Ajani, Jaffer A. Fodor, Miguel Tjulandin, Sergei Moiseyenko, Vladimir M. Chao, Yee Cabral, Sebastiao Majlis, Alejandro Assadourian, Sylvie Van Cutsem, Eric |
| Fecha: |
2007-04-17 2007-04-17 2005-08-20 |
| Publicador: | JOURNAL OF CLINICAL ONCOLOGY |
| Fuente: |
Ver documento |
| Tipo: | Artículo de Revista |
| Tema: |
SUPPORTIVE CARE CANCER CHEMOTHERAPY CARCINOMA (TAXOTERE(R))-CISPLATIN |
| Descripción: | Purpose The purpose of this study was to define the contribution of docetaxel to combination chemotherapy in the outcome of patients with advanced gastric or gastroesophageal adenocarcinoma. We compared the overall response rate (ORR) and safety of docetaxel plus cisplatin (DC) with DC plus fluorouracil (DCF) to select either DC or DCF as the experimental treatment in the ensuing phase III part of trial V-325. Patients and Methods In this phase II randomized study, untreated patients with confirmed advanced gastric or gastroesophageal adenocarcinoma received either DCF (docetaxel 75 mg/m(2), cisplatin 75 mg/m(2) on day 1, and fluorouracil 750 mg/m(2)/d as continuous infusion on days 1 to 5) or DC (docetaxel 85 mg/m(2) and cisplatin 75 mg/m(2) on day 1) every 3 weeks. An independent data monitoring committee (IDMC) was to select one of the two regimens based primarily on ORR and safety profile. Results Of 158 randomly assigned patients, 155 (DCF, n = 79; DC, n = 76) received treatment. The confirmed ORR was 43% for DCF (n = 79) and 26% for DC (n = 76). Median time to progression was 5.9 months for DCF and 5.0 months for DC. Median overall survival time was 9.6 months for DCF and 10.5 months for DC. The most frequent grade 3 and 4 events per patient included neutropenia (DCF = 86%; DC = 87%) and GI (DCF = 56%; DC = 30%). Conclusion Both regimens were active, but DCF produced a higher confirmed ORR than DC. Toxicity profiles of DCF were considered manageable. The IDMC chose DCF for the phase III part of V-325, which compares DCF with cisplatin plus fluorouracil. |
| Idioma: | Inglés |